In vitro determination of Sun Protection Factor on Clays Used for Cosmetic Purposes in Kenya

Ultraviolet radiation is a real problem to human health and it’s said to cause skin cancer and related skin ailments. These diseases are of economic burden in terms of diagnosis, treatment and prevention in low and middle level countries. Commercial sunscreens are considered as the most effective way of preventing the incidences of skin cancer, however they are costly, unavailable and they contain toxic ingredients, which can in the end be cancerous. Sunscreens from natural sources like plants and clay are currently being explored as cheap, reliable, and available and may offer simple alternative health benefits. The purpose of this study was to evaluate the amount of sun protection factor (SPF) offered by cosmetic clays used in Kenya by different communities. The SPF was determined in vitro using 3 M transpore adhesive tapes on twelve clay samples collected randomly from sites used in three counties namely Narok, Bomet and Bungoma. Using a spreading protocol of 2 µg/cm2 transmittances between 280 to 400 nm were measured using a UV 1800 Shimadzu, Japan spectrophotometer. A commercial sunscreen with known SPF was incorporated in the study as a positive control. The SPF values of the clays were found to be between 1.46 and 40.98. The SPF value obtained for the commercial sunscreen differed from the SPF cited by the manufacturer. A second method was used on the commercial sunscreen and values obtained were in close agreement with those used in the first method. This study revealed that clays used for cosmetic purposes offer some form of sun protection to its users. Determination of SPF using Transpore tape is cheap, easy to handle, readily available and rapid. Keywords: Sun Protection factor, Clay

Taking Saratoga from Space-Based Ground Sensors to Ground-Based Space Sensors

The Saratoga transfer protocol was developed by Surrey Satellite Technology Ltd (SSTL) for its Disaster Monitoring Constellation (DMC) satellites. In over seven years of operation, Saratoga has provided efficient delivery of remote-sensing Earth observation imagery, across private wireless links, from these seven low-orbit satellites to ground stations, using the Internet Protocol (IP). Saratoga is designed to cope with high bandwidth-delay products, constrained acknowledgement channels, and high loss while streaming or delivering extremely large files. An implementation of this protocol has now been developed at the Australian Commonwealth Scientific and Industrial Research Organisation (CSIRO) for wider use and testing. This is intended to prototype delivery of data across dedicated astronomy radio telescope networks on the ground, where networked sensors in Very Long Baseline Interferometer (VLBI) instruments generate large amounts of data for processing and can send that data across private IP- and Ethernet-based links at very high rates. We describe this new Saratoga implementation, its features and focus on high throughput and link utilization, and lessons learned in developing this protocol for sensor-network applications.Comment: Preprint of peer-reviewed conference paper accepted by and to appear at the IEEE Aerospace 2011 conference, Big Sky, Montana, March 201

Association between furosemide in premature infants and sensorineural hearing loss and nephrocalcinosis: a systematic review

Abstract Furosemide is a potent loop diuretic commonly and variably used by neonatologists to improve oxygenation and lung compliance in premature infants. There are several safety concerns with use of furosemide in premature infants, specifically the risk of sensorineural hearing loss (SNHL), and nephrocalcinosis/nephrolithiasis (NC/NL). We conducted a systematic review of all trials and observational studies examining the association between these outcomes with exposure to furosemide in premature infants. We searched MEDLINE, EMBASE, CINAHL, and clinicaltrials.gov . We included studies reporting either SNHL or NC/NL in premature infants (< 37 weeks completed gestational age) who received at least one dose of enteral or intravenous furosemide. Thirty-two studies met full inclusion criteria for the review, including 12 studies examining SNHL and 20 studies examining NC/NL. Only one randomized controlled trial was identified in this review. We found no evidence that furosemide exposure increases the risk of SNHL or NC/NL in premature infants, with varying quality of studies and found the strength of evidence for both outcomes to be low. The most common limitation in these studies was the lack of control for confounding factors. The evidence for the risk of SNHL and NC/NL in premature infants exposed to furosemide is low. Further randomized controlled trials of furosemide in premature infants are urgently needed to adequately assess the risk of SNHL and NC/NL, provide evidence for improved FDA labeling, and promote safer prescribing practices.https://deepblue.lib.umich.edu/bitstream/2027.42/146523/1/40748_2018_Article_92.pd

Use of the Delay-Tolerant Networking Bundle Protocol from Space

The Disaster Monitoring Constellation (DMC), constructed by Survey Satellite Technology Ltd (SSTL), is a multisatellite Earth-imaging low-Earth-orbit sensor network where captured image swaths are stored onboard each satellite and later downloaded from the satellite payloads to a ground station. Store-and-forward of images with capture and later download gives each satellite the characteristics of a node in a Delay/Disruption Tolerant Network (DTN). Originally developed for the Interplanetary Internet, DTNs are now under investigation in an Internet Research Task Force (IRTF) DTN research group (RG), which has developed a bundle architecture and protocol. The DMC is currently unique in its adoption of the Internet Protocol (IP) for its imaging payloads and for satellite command and control, based around reuse of commercial networking and link protocols. These satellites use of IP has enabled earlier experiments with the Cisco router in Low Earth Orbit (CLEO) onboard the constellation's UK-DMC satellite. Earth images are downloaded from the satellites using a custom IPbased high-speed transfer protocol developed by SSTL, Saratoga, which tolerates unusual link environments. Saratoga has been documented in the Internet Engineering Task Force (IETF) for wider adoption. We experiment with use of DTNRG bundle concepts onboard the UKDMC satellite, by examining how Saratoga can be used as a DTN convergence layer to carry the DTNRG Bundle Protocol, so that sensor images can be delivered to ground stations and beyond as bundles. This is the first successful use of the DTNRG Bundle Protocol in a space environment. We use our practical experience to examine the strengths and weaknesses of the Bundle Protocol for DTN use, paying attention to fragmentation, custody transfer, and reliability issues

Activin A expression regulates multipotency of mesenchymal progenitor cells

INTRODUCTION. Bone marrow (BM) stroma currently represents the most common and investigated source of mesenchymal progenitor cells (MPCs); however, comparable adult progenitor or stem cells have also been isolated from a wide variety of tissues. This study aims to assess the functional similarities of MPCs from different tissues and to identify specific factor(s) related to their multipotency. METHODS. For this purpose, we directly compared MPCs isolated from different adult tissues, including bone marrow, tonsil, muscle, and dental pulp. We first examined and compared proliferation rates, immunomodulatory properties, and multidifferentiation potential of these MPCs in vitro. Next, we specifically evaluated activin A expression profile and activin A:follistatin ratio in MPCs from the four sources. RESULTS. The multidifferentiation potential of the MPCs is correlated with activin A level and/or the activin A:follistatin ratio. Interestingly, by siRNA-mediated activin A knockdown, activin A was shown to be required for the chondrogenic and osteogenic differentiation of MPCs. These findings strongly suggest that activin A has a pivotal differentiation-related role in the early stages of chondrogenesis and osteogenesis while inhibiting adipogenesis of MPCs. CONCLUSIONS. This comparative analysis of MPCs from different tissue sources also identifies bone marrow-derived MPCs as the most potent MPCs in terms of multilineage differentiation and immunosuppression, two key requirements in cell-based regenerative medicine. In addition, this study implicates the significance of activin A as a functional marker of MPC identity.National Institute of Arthritis, and Musculoskeletal and Skin Diseases; National Institutes of Health (ZO1 AR 41131, 01 DE019156-01

Essays on Western History in Honor of Elwyn B. Robinson

This book was published on the occasion of the retirement of Dr. Elwyn B. Robinson from the Department of History at the University of North Dakota. It features articles by several different historians regarding various subjects in the history of the American West.https://commons.und.edu/und-books/1021/thumbnail.jp

Association between furosemide in premature infants and sensorineural hearing loss and nephrocalcinosis: a systematic review

Abstract Furosemide is a potent loop diuretic commonly and variably used by neonatologists to improve oxygenation and lung compliance in premature infants. There are several safety concerns with use of furosemide in premature infants, specifically the risk of sensorineural hearing loss (SNHL), and nephrocalcinosis/nephrolithiasis (NC/NL). We conducted a systematic review of all trials and observational studies examining the association between these outcomes with exposure to furosemide in premature infants. We searched MEDLINE, EMBASE, CINAHL, and clinicaltrials.gov . We included studies reporting either SNHL or NC/NL in premature infants (< 37 weeks completed gestational age) who received at least one dose of enteral or intravenous furosemide. Thirty-two studies met full inclusion criteria for the review, including 12 studies examining SNHL and 20 studies examining NC/NL. Only one randomized controlled trial was identified in this review. We found no evidence that furosemide exposure increases the risk of SNHL or NC/NL in premature infants, with varying quality of studies and found the strength of evidence for both outcomes to be low. The most common limitation in these studies was the lack of control for confounding factors. The evidence for the risk of SNHL and NC/NL in premature infants exposed to furosemide is low. Further randomized controlled trials of furosemide in premature infants are urgently needed to adequately assess the risk of SNHL and NC/NL, provide evidence for improved FDA labeling, and promote safer prescribing practices